Component Preview
Dr Niamh Buckley is working to develop a treatment for triple negative breast cancer, using technology similar to that used in the COVID-19 vaccine.
Heading 2
Around 15% of breast cancers are classed as triple negative. This form of breast cancer can be more aggressive than other forms of the disease. There are currently limited targeted treatments available for triple negative breast cancer. We urgently need to address this and find new and effective ways to treat people diagnosed with this type of breast cancer.
Heading 3
Niamh and her team use a similar technique to that used in the Pfizer and Moderna COVID-19 vaccines to develop a new way to treat triple negative breast cancer. The treatment aims to stimulate the immune system to recognise and fight the cancer with minimal side effects.
The treatment is targeting a protein called p53. Almost 90% of triple negative breast cancers contain an abnormally large amount of this protein compared to healthy cells. And there is a simple test to check if a tumour has a lot of p53. This means doctors could easily test who is most likely to benefit from the treatment.
Heading 4
- A change to the skin, such as puckering or dimpling
- A change to the skin, such as puckering or dimpling
- A change to the skin, such as puckering or dimpling
- A change to the skin, such as puckering or dimpling
Heading 5
- This is one numbered bullet point and this is a long point. This is one numbered bullet point and this is a long point.
- This is one numbered bullet point and this is a long point. This is one numbered bullet point and this is a long point.
- This is one numbered bullet point and this is a long point. This is one numbered bullet point and this is a long point.
Heading 6
Niamh and her team use a similar technique to that used in the Pfizer and Moderna COVID-19 vaccines to develop a new way to treat triple negative breast cancer. The treatment aims to stimulate the immune system to recognise and fight the cancer with minimal side effects.